Literature DB >> 28854525

Clinical study on minimally invasive liquefaction and drainage of intracerebral hematoma in the treatment of hypertensive putamen hemorrhage.

Ke-Shan Liang1,2,3,1, Jian Ding3,1, Cheng-Bin Yin4, Li-Jing Peng5, Zhen-Chuan Liu6, Xiao Guo2, Shu-Yu Liang7, Yong Zhang3, Sheng-Nian Zhou1.   

Abstract

OBJECTIVE: This study aims to compare the curative effect of different treatment methods of hypertensive putamen hemorrhage, in order to determine an ideal method of treatment; and to explore the curative effect of the application of soft channel technology-minimally invasive liquefaction and drainage of intracerebral hematoma in the treatment of hypertensive putamen hemorrhage.
METHODS: Patients with hypertensive cerebral hemorrhage, who were treated in our hospital from January 2015 to January 2016, were included into this study. Patients were divided into three groups: minimally invasive drainage group, internal medical treatment group and craniotomy group. In the minimally invasive drainage group, puncture aspiration and drainage were performed according to different hematoma conditions detected in brain CT, the frontal approach was selected for putamen and intracerebral hemorrhage, and drainage was reserved until the hematoma disappeared in CT detection. Drug therapy was dominated in the internal medical treatment group, while surgery under general anesthesia was performed to remove the hematoma in the craniotomy group.
RESULTS: Post-treatment neurological function defect scores in minimally invasive drainage group and internal medical group were 16.14 ± 11.27 and 31.43 ± 10.42, respectively; and the difference was remarkably significant (P< 0.01). Post-treatment neurological function defect scores in the minimally invasive drainage group and craniotomy group were 16.14 ± 11.27 and 24.20 ± 12.23, respectively; and the difference was statistically significant (P< 0.05). There was a remarkable significant difference in ADL1-2 level during followed-up in survival patients between the minimally invasive drainage group and internal medical treatment group (P< 0.01), and there was a significant difference in followed-up mortality between these two groups (P< 0.01).
CONCLUSION: Clinical observation and following-up results revealed that minimally invasive drainage treatment was superior to internal medical treatment and craniotomy.

Entities:  

Keywords:  Intracranial hemorrhage; drainage; follow-up studies; hypertensive; minimally invasive; surgical procedures

Mesh:

Year:  2017        PMID: 28854525     DOI: 10.3233/THC-170950

Source DB:  PubMed          Journal:  Technol Health Care        ISSN: 0928-7329            Impact factor:   1.285


  5 in total

1.  Analysis of the Therapeutic Effect and Prognostic Factors of 126 Patients With Hypertensive Cerebral Hemorrhage Treated by Soft-Channel Minimally Invasive Puncture and Drainage.

Authors:  Jiaxun Wu; Sunfu Zhang
Journal:  Front Surg       Date:  2022-04-29

2.  Experience of Using a New Brain Surgery Head Frame and Location Sticker for Treating Spontaneous Intracranial Hematoma.

Authors:  Hongyu Wang; Wenqiang Xin; Jianzhong Cui
Journal:  Front Neurol       Date:  2022-04-27       Impact factor: 4.086

3.  Neuroendoscopic-assisted versus mini-open craniotomy for hypertensive intracerebral hemorrhage: a retrospective analysis.

Authors:  Wenchao Lu; Hui Wang; Kang Feng; Bangxu He; Dong Jia
Journal:  BMC Surg       Date:  2022-05-14       Impact factor: 2.030

4.  Analysis of clinical distribution and drug resistance of klebsiella pneumoniae pulmonary infection in patients with hypertensive intra cerebral hemorrhage after minimally invasive surgery.

Authors:  Wei Li; Li Xu; Haige Zhao; Shanshan Zhu
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

5.  Comparison and analysis of the efficacy and safety of minimally invasive surgery and craniotomy in the treatment of hypertensive intracerebral hemorrhage.

Authors:  Jixin Zhang; Shiyong Lu; Suzhen Wang; Naiyun Zhou; Guoliang Li
Journal:  Pak J Med Sci       Date:  2018 May-Jun       Impact factor: 1.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.